ETFs Scholar Rock Holding Corporation

SRRK

US80706P1030

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:37:56 2026-08-11 EDT			5-day change	1st Jan Change
52.20 ^USD	+0.61%		+8.99%	+18.25%

08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-10	Novo Nordisk works to address FDA's findings at Indiana plant	FW

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.

Employees

289

Sector

Biotechnology & Medical Research

More about the company